Table 3.
Numbers of participants developing malignancies in ADOPT
| Variable | Metformin | Rosiglitazone | Glibenclamide |
|---|---|---|---|
| n | 1,454 | 1,456 | 1,441 |
| Study exposure (person-years) | 4,906 | 4,954 | 4,244 |
| Malignancies | |||
| All | 56 (3.9) | 60 (4.1) | 64 (4.4) |
| All non-skin | 50 (3.4) | 55 (3.8) | 55 (3.8) |
| Breast | 6 (1.0) | 6 (0.9) | 3 (0.5) |
| Endocrine | 0 | 0 | 2 (0.1) |
| Colorectal | 7 (0.5) | 4 (0.3) | 10 (0.7) |
| Gastric | 1 (0.1) | 1 (0.1) | 1 (0.1) |
| Hepato-biliary | 0 | 3 (0.2) | 1 (0.1) |
| Intestinal | 1 (0.1) | 1 (0.1) | 0 |
| Oral and oesophagus | 2 (0.1) | 3 (0.2) | 3 (0.2) |
| Pancreatic | 0 | 5 (0.3) | 0 |
| Haematological | 3 (0.2) | 4 (0.3) | 4 (0.3) |
| Metastases unknown | 0 | 2 (0.1) | 2 (0.1) |
| Unspecified | 2 (0.1) | 3 (0.2) | 1 (0.1) |
| Nervous system | 2 (0.1) | 0 | 0 |
| Bladder | 4 (0.3) | 2 (0.1) | 4 (0.3) |
| Renal | 1 (0.1) | 2 (0.1) | 2 (0.1) |
| Cervix/uterine | 1 (0.2) | 1 (0.2) | 3 (0.5) |
| Ovarian | 0 | 3 (0.5) | 0 |
| Prostatic | 10 (1.2) | 10 (1.2) | 9 (1.1) |
| Testicular | 1 (0.1) | 0 | 0 |
| Lung | 6 (0.4) | 5 (0.3) | 7 (0.5) |
| Nasal/laryngeal | 1 (0.1) | 0 | 2 (0.1) |
| Melanoma | 2 (0.1) | 2 (0.1) | 2 (0.1) |
| Skin (non-melanoma) | 7 (0.5) | 5 (0.3) | 11 (0.8) |
| Basal cell carcinoma | 6 (0.4) | 5 (0.3) | 10 (0.7) |
| Other | 1 (0.1) | 0 | 1 (0.1) |
| Sarcomas | 0 | 1 (0.1) | 0 |
Data are number (n) of patients (%) with a neoplasm reported as a serious adverse event
Per cent values for prostate and for breast, cervix/uterine and ovarian cancer are based on men only and women only